Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium adolescentis OP820
- Development stage
- Preclinical
- Lead developer
- Sungsu Park
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Bifidobacterium adolescentis OP820 is a microbiome-derived, strict anaerobic probiotic strain investigated for its immunomodulatory and anti-tumor properties. It specifically adheres to the mucin-rich glycocalyx of the intestinal epithelium by inducing the expression of MUC13 and MUC17. In preclinical models, OP820 has demonstrated the ability to resolve chronic intestinal inflammation and suppress colorectal cancer progression. Its mechanism involves the modulation of cytokine and stromal networks, including the upregulation of repair-associated genes (CCL8, TGFA, MMP12) and the suppression of pro-inflammatory markers (TSLP, FLT3LG, IL18). Notably, it has shown efficacy when administered intravenously in tumor models, where it localizes within the tumor microenvironment to reprogram the immune state and reduce tumor burden.
- Other names
- B. adolescentis OP820
02
Targets
MUC17 (Mucin 17, cell surface associated)MUC13 (Mucin-13)
Beyond the preview
Go deeper on Bifidobacterium adolescentis OP820.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium adolescentis OP820.